SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2026
Assessing the economic burden of complicated urinary tract infection: A systematic literature review.
Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy.The Indian journal of medical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplicated urinary tract infections (cUTIs) arise in patients with structural or functional abnormalities of the genitourinary tract or those with nonurogenital comorbidities. cUTIs can be associated with high healthcare resource utilization (HCRU). We conducted a systematic literature review (SLR) to understand the economic burden of cUTI in a selection of countries likely to have early adoption of innovative antibiotic combination regimens.
methodsThe SLR was conducted to identify observational studies evaluating the burden of cUTI in France, Italy, Germany, Spain, the United Kingdom, China, Japan, and the United States (US) for 2013-2023 (PROSPERO-CRD42023454794) using PubMed, Embase, Cochrane, and EconLit databases, with no language limitations.
resultsOf 1,041 studies identified, 154 from databases were selected for full-text review; of these, 53 met the economic inclusion criteria, reporting direct costs and/or healthcare utilization. Mean hospitalization costs per cUTI varied from $2,747 in China to $32,790 for catheter-associated UTI (CAUTI) acquired in the hospital among US children. Length of stay (LOS) was the most common HCRU outcome reported. Across 3 multicountry studies, LOS for cUTI hospitalization was similar, with a median length of 7 days. Patients with CAUTI had longer LOS than did controls.
conclusionsAvailable evidence from the US studies indicates that economic burden associated with cUTI is substantial. However, except for the US, direct costs were missing or reported in only 1 or 2 studies for each of the other countries examined. Similarly, HCRU outcomes were missing or reported in only a few studies, except for the US and Spain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.